Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 3000
Summary
- Conditions
- COVID-19
- Pneumonia
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Pragmatic, Bayesian adaptive randomized controlled trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a prospective, open-label, multicentre, Bayesian adaptive randomized clinical trial to establish whether therapeutic-dose parenteral anticoagulation improves outcomes for patients hospitalized with COVID-19 (e.g., reduces intubation or mortality). Participants will be randomized either to th...
This is a prospective, open-label, multicentre, Bayesian adaptive randomized clinical trial to establish whether therapeutic-dose parenteral anticoagulation improves outcomes for patients hospitalized with COVID-19 (e.g., reduces intubation or mortality). Participants will be randomized either to the investigational arm (therapeutic anticoagulation with heparin for 14 days or until "recovery" [defined as hospital discharge or liberation from supplemental oxygen if initially required], whichever comes first), or to the control arm (usual care, including thromboprophylactic dose anticoagulation according to local practice).
Tracking Information
- NCT #
- NCT04372589
- Collaborators
- University Health Network, Toronto
- Investigators
- Principal Investigator: Patrick R. Lawler, MD, MPH Peter Munk Cardiac Centre/University Health Network Principal Investigator: Ewan C. Goligher, MD, PhD University Health Network, Toronto Principal Investigator: Ryan Zarychanski, MD, MSc University of Manitoba
Get Well Soon